product name QNZ (EVP4593)
References: Bioorg Med Chem. 2003 Feb 6;11(3):383-91; Chem Biol. 2011 Jun 24;18(6):777-93.
356.42
Formula
C22H20N4O
CAS No.
545380-34-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 5 mg/mL warming (14.0 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: <1 mg/mL (slightly soluble or insoluble)
Solubility (In vivo)
0.5% hydroxyethyl cellulose: 30 mg/mL
Chemical Name
4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine
other peoduct :
| EVP4593 inhibits TNF-a production from murine splenocytes stimulated with LPS with IC50 of 7 nM. EVP4593 (300 nM) entails a significant decrease of amplitude of store-operated currents (approximately by 60%), induced by application of 1 μM thapsigargin in Htt138Q cells, thus prevents abnormal store-operated calcium entry. | |
|---|---|
| In Vivo | EVP4593 (1 mg/kg, i.p.) dose-dependently inhibits carrageenin-induced paw edema in rats. |
| Animal model | male SD rats with carrageenin induced paw edema |
| Formulation & Dosage | 0.5% hydroxypropyl cellulose; 1 mg/kg; i.p injection |
| References | [1] Tobe M, et al. Bioorg Med Chem, 2003, 11(3), 383-391. |
